TP53 gene deletion in esophageal cancer tissues of patients and its clinical significance

Molecular Medicine Reports

Volumn 7, Issue 1, 2013, Pages 122-126

  Niyaz, Madiniyet ^a   Turghun, Abdugheni ^b   Ping, Zhang Hai ^b   Zhu, Zhang ^b   Sheyhedin, Ilyar ^b   Ren, Cai ^a   Awut, Idiris ^b  

^a Medical Research Center   (China)

^b XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; FISH; Kazakh; TP53 gene

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DOSAGE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MOLECULAR PATHOLOGY; TUMOR DIFFERENTIATION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873816733     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1162     Document Type: Article

References (22)

1. Lu XM, Zhang YM, Lin RY, Arzi G, Wang X, Zhang YL, Zhang Y, Wang Y, and Wen H: Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang. World J Gastroenterol 11: 3651-3654, 2005.
2. Schmale H and Bamberger C: A novel protein with strong homology to the tumor suppressor p53. Oncogene 15: 1363-1367, 1997.
3. Graesslin O, Chantot-Bastaraud S, Lorenzato M, Birembaut P, Quéreux C and Daraï E: Fluorescence insitu hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: prognostic value and relation to ploidy. Ann Surg Oncol 15: 484-492, 2008.
4. Halling KC and Kipp BR: Fluorescence insitu hybridization in diagnostic cytology. Hum Pathol 38: 1137-1144, 2007.
5. Li WJ and Duan JX: Detecting of p53 gene heterozygosity loss in esophageal carcinoma tissues. JZU Med Sci 39: 499-501, 2004.
6. Hollstein MC, Metcalf RA, Welsh JA, Montesano R and Harris CC: Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 87: 9958-9961, 1990.
7. Audrézet MP, Robaszkiewicz M, Mercier B, etal: TP53 gene mutation profile in esophageal squamous cell carcinomas. Cancer Res 53: 5745-5749, 1993.
8. Nakamura H, Saji H, Idiris A, etal: Chromosomal instability detected by fluorescence insitu hybridizationin surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res 9: 2294-2299, 2003.
9. Cheng ZQ, Wang XM, Shan J, etal: Detection of p53 gene deletion in primary lung cancer by dual-FISH technique and its clinical significance. Clin Med Chin 26: 368-371, 2010.
10. Uchino S, Saito T, Inomata M, Osawa N, Chikuba K, Etoh K and Kobayashi M: Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol 26: 287-292, 1996.
11. Manoel-Caetano Fda S, Borim AA, Caetano A, Cury PM and Silva AE: Cytogenetic alterations in chagasic achalasia compared to esophageal carcinoma. Cancer Genet Cytogenet 149: 17-22, 2004.
12. Curtis C, Harris MD and Hollstein MC: Clinical implications of the p53 tumor suppessor gene. N Eng J Med 329: 1318-1325, 1993.
13. Smith DR, Ji CY and Coh HS: Prognostic significance of p53 over expression and mutation in colorectal adrecarcinomas. Br J Cancer 74: 216-223, 1996.
14. Fritcher EG, Brankley SM, Kipp, BR, etal: A comparison of conventional cytology, DNA ploidy analysis, and fluorescence insitu hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol 39: 1128-1135, 2008.
15. Kawai T, Hiroi S, Nakanishi K, Sakurai Y and Torikata C: Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence insitu hybridization. Pathol Int 54: 413-419, 2004.
16. Varshney D, Zhou YY, Geller SA and Alsabeh R: Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing Hercep Test and Path Vysion FISH assay. Am J Clin Pathol 121: 70-77, 2004.
17. Fujiwara T, Cai DW, Georges R, etal: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86: 1458-1462, 1994.
18. Lu SM, Cheng CL and Sheng BY: Immunohistochemical detection of p53 protein altered expression in 1364 patients with maligant tumors and its clinicopathological significance. Chin J Cancer 20: 620-623, 2001.
19. Li JD, Li H and Shen ZY: Esophageal spontaneous apoptosis and nuclear value-added antigen, relationship with p53. Chin J Oncol 20: 415-417, 1998.
20. Idiris A, Madiniyet N, Hadeti B, Zhang Z, Ilyar S and Wen H: Molecular pathological diagnosis for early esophageal cancer in Kazakh patients. Oncol Lett 13: 549-553, 2012.
21. Abedi-Ardekani B, Kamangar F, Sotoudeh M, etal: Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran. PLoS One 6: e29488, 2011.
22. King SI, Purdie CA, Bray SE, Quinlan PR, Jordan LB, Thompson AM and Meek DW: Immunohistochemical detection of Polo-like Kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome. Breast Cancer Res 14: 40, 2012.